Cladribine
A purine nucleoside analog that selectively destroys lymphocytes by accumulating in cells with high deoxycytidine kinase activity and low 5'-nucleotidase activity, disrupting DNA synthesis and repair. It is used for hairy cell leukemia, multiple sclerosis, and other lymphoid malignancies. Profound and prolonged lymphopenia is a characteristic effect requiring careful infectious complication monitoring.
分子量
285.6900 g/mol
LogP
0.80
TPSA
119.00 Ų
Lipinski 五规则
符合
治疗领域
作用机制
Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.
二维结构
Cite this structure
Embed this structure
SMILES
Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
InChI
InChI=1S/C10H12ClN5O3/c11-10-14-8(12)7-9(15-10)16(3-13-7)6-1-4(18)5(2-17)19-6/h3-6,17-18H,1-2H2,(H2,12,14,15)/t4-,5+,6+/m0/s1
Molecular Formula
C10H12ClN5O3
HBD / HBA
3 / 7
可旋转键数
2
重原子数
19
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
常见问题
A purine nucleoside analog that selectively destroys lymphocytes by accumulating in cells with high deoxycytidine kinase activity and low 5'-nucleotidase activity, disrupting DNA synthesis and repair. It is used for hairy cell leukemia, multiple sclerosis, and other lymphoid malignancies. Profound and prolonged lymphopenia is a characteristic effect requiring careful infectious complication monitoring.
Functions as a nucleoside analog that is incorporated into viral or cellular DNA/RNA during replication, causing chain termination or coding errors that inhibit pathogen proliferation.
Yes, Cladribine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1619. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 20279. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cladribine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cladribine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cladribine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cladribine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cladribine"></drugfyi-drug>